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Bavarian Nordic, Inc. is developing poxvirus-based cancer
immunotherapies. These therapies employ vaccinia-,
Modified Vaccinia Ankara (MVA)-, and fowlpox-based
vectors that were engineered to express one or more
tumor-associated antigens (TAA). These vectors are used
alone or in prime-boost strategies to generate an active
immune response against a variety of cancers. The lead
candidate PROSTVAC® employs a prime-boost strategy
using vaccinia and fowlpox expressing PSA and TRICOM
(TM) and is currently in a global Phase III clinical trial
(PROSPECT) for castration-resistant metastatic prostate
cancer. Other products such as recombinant MVA-BN®
expressing HER2 have been tested in early phase clinical
trials for the treatment of breast cancer. To further
enhance the anti-tumor efficacy of the poxvirus-based
immunotherapy, the present preclinical study focuses on
combining the breast cancer candidate therapy MVA-BN®
HER2 with a monoclonal antibody that blocks the activity
of CTLA-4, an immune checkpoint protein that down-
regulates T cell activation. In the CT26-HER2 experimen-
tal lung metastasis model, the median survival time
increased from 30 days in untreated mice to 49.5 days
with MVA-BN® HER2 treatment while anti-CTLA-4
treatment by itself showed little survival benefit (median
survival 35 days). In contrast, MVA-BN® HER2 in combi-
nation with anti-CTLA-4 significantly increased the survi-
val to greater than 100 days (p<0.0001) in more than 50%
of the mice. At 100 days, the lungs of the surviving mice
were examined and there were no visible tumors. Further-
more, phenotypic analysis was performed on tumor infil-
trating lymphocytes. At day 25, an increase in the number
of regulatory T cells (CD4+ FoxP3+) was observed in the
lungs of untreated and anti-CTLA-4 treated mice which
correlated with increased pulmonary tumor burden. Effec-
tor cells (CD127+ KLRG1+/-) increased with MVA-BN®
HER2 treatment and were further increased in combina-
tion with anti-CTLA-4. The inducible co-stimulatory
molecule (ICOS) also increased with MVA-BN® HER2
treatment and was enhanced with anti-CTLA-4 treatment
on both CD4+ and CD8+ T cells. Overall these animal
studies demonstrate that enhanced efficacy and synergistic
activity of poxvirus immunotherapies can be achieved in
combination with anti-CTLA-4 and provide insight into
the phenotype of the immune cells. Additional checkpoint
inhibitors in combination with poxvirus vectors are being
actively studied and will be discussed in greater detail.
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